LifeSci Capital analyst Francois Brisebois maintained a Buy rating on Praxis Precision Medicines today and set a price target of $373.00. The company’s shares opened today at $158.29.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brisebois covers the Healthcare sector, focusing on stocks such as Kala Pharmaceuticals, Praxis Precision Medicines, and Avadel Pharmaceuticals. According to TipRanks, Brisebois has an average return of -4.7% and a 35.42% success rate on recommended stocks.
Praxis Precision Medicines has an analyst consensus of Strong Buy, with a price target consensus of $191.50, representing a 20.98% upside. In a report released today, Guggenheim also maintained a Buy rating on the stock with a $350.00 price target.
The company has a one-year high of $91.83 and a one-year low of $26.70. Currently, Praxis Precision Medicines has an average volume of 466.1K.
Read More on PRAX:
Disclaimer & DisclosureReport an Issue
- Buy Rating Affirmed for Praxis Precision Medicines Following Positive Phase 3 Study Results
- Praxis Precision price target raised to $300 from $65 at Jefferies
- Praxis Precision price target raised to $350 from $155 at Guggenheim
- Why Is Praxis Precision Medicines (PRAX) Stock Up 155% Today?
- Praxis Precision Medicines Announces Positive Phase 3 Results
/A%20concept%20image%20of%20a%20flying%20car_%20Image%20by%20Phonlamai%20Photo%20via%20Shutterstock_.jpg)
/A%20concept%20image%20of%20space_%20Image%20by%20Canities%20via%20Shutterstock_.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)